Assessment of chloroquine as a modulator of immune activation to improve <scp>CD4</scp> recovery in immune nonresponding <scp>HIV</scp>‐infected patients receiving antiretroviral therapy

Abstract

CQ was well tolerated in patients with low CD4 T-cell counts despite long-term effective ART; however, 24 weeks of CQ treatment did not improved CD4 T-cell recovery, lymphoid and myeloid immune activation or inflammatory markers.